» Articles » PMID: 30499165

Long Noncoding RNAs As Regulators of Cancer Immunity

Overview
Journal Mol Oncol
Date 2018 Dec 1
PMID 30499165
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

Long noncoding RNAs (lncRNAs) are increasingly known to be important in cancer as they directly interact with the cell cycle, proliferation pathways and microbiome balance. Moreover, lncRNAs regulate the immune system: they do not directly encode proteins of innate or adaptive immunity, but regulate immune cell differentiation and function, such as dendritic cell activity, T cell ratio and metabolism. The result of this complex interaction is that lncRNAs regulate cancer processes through a complex multimodal system involving immunity, metabolism and infection. The possible functions of lncRNAs and their roles in the regulation of cancer immunity will be reported and discussed in the present review. Recent studies showed their function as regulators in the tumour microenvironment (TME), epithelial-mesenchymal transition, microbiota, metabolism and immune cell differentiation. However, there is not much knowledge regarding their roles in cancer immunity regulation. Thus, the main aim of this review is to describe lncRNAs that have specifically been associated with immunity, the immune cycle and the TME.

Citing Articles

Biological functions and affected signaling pathways by Long Non-Coding RNAs in the immune system.

Ghahramani Almanghadim H, Karimi B, Valizadeh S, Ghaedi K Noncoding RNA Res. 2024; 10:70-90.

PMID: 39315339 PMC: 11417496. DOI: 10.1016/j.ncrna.2024.09.001.


Immune-Related Long Non-Coding RNA Signature Determines Prognosis and Immunotherapeutic Coherence in Esophageal Cancer.

Uttam V, Kapoor H, Rana M, Yadav R, Prakash H, Jain M Cancer Inform. 2024; 23:11769351241276757.

PMID: 39282627 PMC: 11401149. DOI: 10.1177/11769351241276757.


Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.

Arshi A, Mahmoudi E, Raeisi F, Dehghan Tezerjani M, Bahramian E, Ahmed Y Front Immunol. 2024; 15:1446937.

PMID: 39257589 PMC: 11384988. DOI: 10.3389/fimmu.2024.1446937.


Identification of potential novel N6-methyladenosine effector-related lncRNA biomarkers for serous ovarian carcinoma: a machine learning-based exploration in the framework of 3P medicine.

Ye L, Tong X, Pan K, Shi X, Xu B, Yao X Front Pharmacol. 2024; 15:1351929.

PMID: 38895621 PMC: 11185051. DOI: 10.3389/fphar.2024.1351929.


A novel immune‑related lncRNA as a prognostic biomarker in HER2 breast cancer.

Li X, Meng Y, Gu B Oncol Lett. 2024; 27(6):269.

PMID: 38686356 PMC: 11057035. DOI: 10.3892/ol.2024.14402.


References
1.
Krawczyk M, Emerson B . p50-associated COX-2 extragenic RNA (PACER) activates COX-2 gene expression by occluding repressive NF-κB complexes. Elife. 2014; 3:e01776. PMC: 4017649. DOI: 10.7554/eLife.01776. View

2.
Xu J, Cao X . Long noncoding RNAs in the metabolic control of inflammation and immune disorders. Cell Mol Immunol. 2018; 16(1):1-5. PMC: 6318285. DOI: 10.1038/s41423-018-0042-y. View

3.
Zhang P, Cao L, Fan P, Mei Y, Wu M . LncRNA-MIF, a c-Myc-activated long non-coding RNA, suppresses glycolysis by promoting Fbxw7-mediated c-Myc degradation. EMBO Rep. 2016; 17(8):1204-20. PMC: 4967955. DOI: 10.15252/embr.201642067. View

4.
Fan C, Tang Y, Wang J, Xiong F, Guo C, Wang Y . Role of long non-coding RNAs in glucose metabolism in cancer. Mol Cancer. 2017; 16(1):130. PMC: 5525357. DOI: 10.1186/s12943-017-0699-3. View

5.
Atianand M, Hu W, Satpathy A, Shen Y, Ricci E, Alvarez-Dominguez J . A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain Inflammation. Cell. 2016; 165(7):1672-1685. PMC: 5289747. DOI: 10.1016/j.cell.2016.05.075. View